News
About the PCSK9 Education and Research Forum
PCSK9 Education and Research Forum is the independent resource on PCSK9 science and its translation into critically important new treatments to lower low density lipoprotein cholesterol (LDL-C), which promise to transform the prognosis of millions of patients with hypercholesterolaemia (cholesterol disorders), accelerated atherosclerotic vascular heart disease and a high risk of premature cardiovascular (CV) death and disability.Aims & ObjectivesMission StatementEditorial BoardPartnership & OutreachForthcoming Meetings
Download Now: New Slide Deck Programme
Previous slide decks focused on landmark studies which used a monoclonal antibody approach to inhibit PCSK9. The next in this series discusses inclisiran, a small interfering RNA therapy, which prevents production of PCSK9 at its primary source in the liver.
Find out more »
Virtual meeting
November 13-17, 2020
Weighing up STRENGTH – report and videos
Evinacumab in refractory hypercholesterolaemia
Novel PCSK9 therapies
Hot Topics
13th Closed Virtual Meeting of the Editorial Board of PCSK9 Forum
Keynote – Post CVD event depression: The prequel and sequel
Prof. David L. Hare presents an objective overview of the evidence for depression and cardiovascular disease, taking the following questions in turn. Does depression cause cardiovascular disease? And does cardiovascular disease cause depression?
Watch the webcast
Keynote – Lipoprotein(a): “The proof of the pudding is in the trial”
Prof. Joseph L. Witztum overviews the evolving evidence for lipoprotein(a) as a cardiovascular risk factor, culminating in the Lp(a)HORIZON outcomes study. If positive, findings from this trial will have important public health implications.
Watch the webcast
From the Editors
SAMSON’s undoing is in the details
Prof. Robert S. Rosenson, Mount Sinai Icahn School of Medicine, New York, USA discusses results from the SAMSON trial of symptoms reported with statin treatment.
Other related reports:
Statin intolerance back in the news: ASCOT-LLA report argues for a nocebo effect
Read the report
Statin intolerance – 50% higher risk of recurrent heart attack in statin intolerant patients
Read the report
Adverse effects of long-term statin therapy: New statement from the EAS Consensus Panel
Read the report
Latest Views
Meet our Editorial Board
View all our Editorial Board
Prof John ChapmanResearch Professor at the University of Pierre and Marie Curie
Prof Henry GinsbergDirector, Irving Institute for Clinical and Translational Research
Dr Michel FarnierClinician based at Point Medical, Dijon, France
Prof Frederick RaalDirector, Carbohydrate & Lipid Metabolism Research Unit
Prof Anthony WierzbickiConsultant in Metabolic Medicine/Chemical Pathology
